Overview

MaxCyte has developed CARMA™, a novel and proprietary technology for the development of non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies. CARMA [derived from CAR mRNA] utilizes MaxCyte’s Flow Electroporation® technology for highly efficient, non-viral, delivery of one or more mRNA(s) into non-activated PBMCs (peripheral blood mononuclear cells) or isolated immune cells such as T- or NK-cells. CARMA offers the potential for a safer cell therapy, as a result of transient expression of receptor(s) and a non-viral delivery approach. Together, CARMA and the EXPERT™ family of instruments also offer the potential for a significantly streamlined, scalable, and cost-effective GMP manufacturing process without the complexity of virus-based products.

OUR PIPELINE

Our CARMA knowledge and experience, coupled with our strong and growing non-clinical and translational research program and established GMP cell processing capabilities forms the basis of our cell therapy R&D platform and underscores the potential for generating a pipeline of highly differentiated, CARMA cell therapies for cancer as well as other diseases with serious unmet needs.

To date, supported by preclinical efficacy, our lead CARMA program, MCY-M11, a mesothelin directed CAR-PBMC therapy, is being evaluated in a Phase I clinical trial for ovarian cancer and peritoneal mesothelioma [NCT03608618]. In addition, we are also advancing research and development of next-generation CARMA-based cell therapies — those potentially engineered with functionality uniquely amenable to the CARMA approach — directed to mesothelin and other novel, undisclosed targets.

CARMA™ IN THE NEWS

CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting

November 9, 2020
Read Full Release

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11

August 18, 2020
Read Full Release

MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

May 18, 2020
Read Full Release

MaxCyte Provides Business Update Related to COVID-19 Pandemic

April 9, 2020
Read Full Release

MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update

December 19, 2019
Read Full Release

MaxCyte to Present at BIO-Europe 2019

November 7, 2019
Read Full Release

MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients

October 24, 2019
Read Full Release

MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum

October 15, 2019
Read Full Release

MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings

September 30, 2019
Read Full Release

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

July 23, 2019
Read Full Release

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

May 8, 2019
Read Full Release

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

May 1, 2019
Read Full Release

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe

March 18, 2019
Read Full Release

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019

December 19, 2018
Read Full Release

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®

October 30, 2018
Read Full Release

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

October 10, 2018
Read Full Release

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences

August 29, 2018
Read Full Release

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

16 July 2018
Read Full Release

MaxCyte, Inc. to Present at 2018 BIO International Convention

May 29, 2018
Read Full Release

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer

April 25, 2018
Read Full Release

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month

March 12, 2018
Read Full Release

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting

March 2, 2017
Read Full Release

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies

December 21, 2016
Read Full Release

MaxCyte Appoints Executive Vice President, Business and Strategic Development

November 2, 2016
Read Full Release

MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies

April 21, 2015
Read Full Release

CARMA™ Scientific Publications